UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 117

Sortiert nach

The challenges of translation

EMBO molecular medicine, 2019-12, Vol.11 (12), p.e10874-n/a

2019

Volltextzugriff (PDF)

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma

Frontiers in immunology, 2022-10, Vol.13, p.1002898-1002898

2022

Volltextzugriff (PDF)

Identification of CD318 (CDCP1) as novel prognostic marker in AML

Annals of hematology, 2020-03, Vol.99 (3), p.477-486

2020

Volltextzugriff (PDF)

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives

Cancers, 2021-02, Vol.13 (3), p.549

2021

Volltextzugriff (PDF)

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer

EMBO molecular medicine, 2021-02, Vol.13 (2), p.e11902-n/a

2021

Volltextzugriff (PDF)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer

Frontiers in immunology, 2023-04, Vol.14, p.1163136-1163136

2023

Volltextzugriff (PDF)

Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro

Frontiers in immunology, 2023-03, Vol.14, p.1112505-1112505

2023

Volltextzugriff (PDF)

Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

Frontiers in oncology, 2024-02, Vol.14, p.1351901-1351901

2024

Volltextzugriff (PDF)

Identification of CD105 (endoglin) as novel risk marker in CLL

Annals of hematology, 2022-04, Vol.101 (4), p.773-780

2022

Volltextzugriff (PDF)

1353 An Fc-optimized B7-H3-targeting antibody for treatment of ovarian cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1507-A1507

2023

Volltextzugriff (PDF)

Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia

Molecular therapy, 2015-04, Vol.23 (4), p.648-655

2015

Volltextzugriff (PDF)

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity

Neoplasia (New York, N.Y.), 2018-11, Vol.20 (11), p.1150-1160

2018

Volltextzugriff (PDF)

Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status

The Journal of immunology (1950), 2014-10, Vol.193 (8), p.4261-4272

2014

Volltextzugriff (PDF)

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma

BMJ open, 2020-10, Vol.10 (10), p.e039639-e039639

2020

Volltextzugriff (PDF)

RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia

Cancer research (Chicago, Ill.), 2013-01, Vol.73 (2), p.683-694

2013

Volltextzugriff (PDF)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

Journal of hematology and oncology, 2023-08, Vol.16 (1), p.1-96, Article 96

2023

Volltextzugriff (PDF)

An Fc‐optimized NKG2D‐immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia

International journal of cancer, 2015-03, Vol.136 (5), p.1073-1084

2015

Volltextzugriff (PDF)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e003882

2022

Volltextzugriff (PDF)

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas

Frontiers in immunology, 2021-04, Vol.12, p.653081-653081

2021

Volltextzugriff (PDF)

1365 An immunocytokine with target cell-restricted IL-15 activity for induction of anti-tumor immunity against acute myeloid leukemia

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1521-A1521

2023

Volltextzugriff (PDF)

1366 B7-H3xCD3 bispecific antibody as novel treatment option in HER2-negative breast cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1522-A1522

2023

Volltextzugriff (PDF)

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.143-143, Article 143

2019

Volltextzugriff (PDF)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies

Journal for immunotherapy of cancer, 2022-02, Vol.10 (2), p.e003655

2022

Volltextzugriff (PDF)

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia

Cancers, 2021-04, Vol.13 (7), p.1632

2021

Volltextzugriff (PDF)

IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases

Cancers, 2022-08, Vol.14 (16), p.3941

2022

Volltextzugriff (PDF)

1 – 25 von 117

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(114)

Publikationsform

Artikel
(116)
Buchkapitel
(1)

Sprache

Englisch
(117)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The challenges of translation

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma

Identification of CD318 (CDCP1) as novel prognostic marker in AML

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer

Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro

Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

Identification of CD105 (endoglin) as novel risk marker in CLL

1353 An Fc-optimized B7-H3-targeting antibody for treatment of ovarian cancer

Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity

Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma

RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

An Fc‐optimized NKG2D‐immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas

1365 An immunocytokine with target cell-restricted IL-15 activity for induction of anti-tumor immunity against acute myeloid leukemia

1366 B7-H3xCD3 bispecific antibody as novel treatment option in HER2-negative breast cancer

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia

IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases

Suchergebnisse filtern